<p>Checkpoint Therapeutics（納斯達克：CKPT - 獲取免費報告）於週五公佈了季度財報。該公司報告每股收益為（$0.69），低於分析師一致預期的（$0.22），差距為（$0.47），據 Zacks 報道。</p>
<h2>Checkpoint Therapeutics 股票上漲 0.2%</h2>
<p>CKPT 在週五的交易時段上漲了$0.01，達到$4.04。該公司股票交易量為 522,554 股，而其平均交易量為 1,124,079 股。該股票的市值為 1.9729 億美元，市盈率為-2.20，貝塔值為 1.41。Checkpoint Therapeutics 的 1 年最低價為$1.38，1 年最高價為$4.50。該股票的 50 日移動平均價為$3.32，200 日移動平均價為$3.25。</p>
<h2>分析師評級變動</h2>
<p>CKPT 成為多份研究分析師報告的主題。HC Wainwright 在 3 月 11 日的報告中重申了 “中性” 評級，並將 Checkpoint Therapeutics 的目標價設定為$4.10。Lake Street Capital 在 3 月 10 日的研究報告中重新發布了 “持有” 評級，並將目標價下調至$4.10（之前為$7.00）。最後，D. Boral Capital 在 3 月 10 日的報告中重申了 “買入” 評級，並將目標價下調至$4.80（之前為$9.00）。</p>
<p><strong>閲讀我們關於 CKPT 的最新股票報告</strong></p>
<h2>Checkpoint Therapeutics 的內部買賣</h2>
<p>在其他 Checkpoint Therapeutics 的新聞中，首席財務官 William Garrett Gray 在 2 月 6 日的交易中出售了 74,110 股公司的股票。該股票以平均價格$3.67 出售，總交易額為$271,983.70。交易後，首席財務官現在持有 1,458,644 股公司的股票，價值$5,353,223.48。此次交易使其持股減少了 4.84%。該出售在向證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。此外，首席執行官 James F. Oliviero III 在 2 月 7 日的交易中出售了 9,233 股公司的股票。該股票以平均價格$3.41 出售，總價值為$31,484.53。出售完成後，首席執行官現在直接持有 3,785,350 股公司的股票，價值約為$12,908,043.50。此次交易使其持股減少了 0.24%。該出售的披露信息可在此找到。在過去三個月中，內部人士已出售 93,674 股公司股票，價值$336,011。內部人士持有公司股票的比例為 2.10%。</p>
<h2>關於 Checkpoint Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Checkpoint Therapeutics, Inc.是一家臨牀階段的免疫療法和靶向腫瘤學公司，專注於在美國和國際上獲取、開發和商業化新型治療方案，以治療實體腫瘤癌症患者。該公司的主要抗體產品候選藥物是 Cosibelimab，目前正在進行針對選定復發或轉移性癌症患者的 1 期臨牀試驗；CK-302 是一個針對血液惡性腫瘤和實體腫瘤的預臨牀試驗產品候選藥物。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Checkpoint Therapeutics</li>
<li>投資商品：它們是什麼？如何投資？</li>
<li>MarketBeat 周度回顧 – 03/24 - 03/28</li>
<li>深入瞭解買賣差價</li>
<li>現在應該購買 UPS 股票嗎？深入分析其 5 年低點</li>
<li>ETF 會支付股息嗎？你需要知道的</li>
<li>4 只醫療保健股票大幅上漲——還有更多收益在後</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0tQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0tQVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Checkpoint Therapeutics 嗎？</h2>
<p>在你考慮 Checkpoint Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Checkpoint Therapeutics 並不在名單上。</p>
<p>雖然 Checkpoint Therapeutics 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Checkpoint醫療

<p>Checkpoint Therapeutics（納斯達克代碼：CKPT）報告季度每股收益為（$0.69），低於分析師預期的（$0.22），差距為（$0.47）。股價上漲 0.2%，至$4.04，市值為 1.9729 億美元。分析師的評級意見不一，HC Wainwright 和 Lake Street Capital 分別維持 “中性” 和 “持有” 評級，而 D. Boral Capital 則給予 “買入” 評級。內部交易方面，首席財務官 William Garrett Gray 出售了 74,110 股，首席執行官 James F. Oliviero III 出售了 9,233 股。該公司專注於免疫療法和腫瘤治療</p>

<p>Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.47), Zacks reports.</p>
<div class="lb-trans"><p>Checkpoint Therapeutics（納斯達克：CKPT - 獲取免費報告）於週五公佈了季度財報。該公司報告每股收益為（$0.69），低於分析師一致預期的（$0.22），差距為（$0.47），據 Zacks 報道。</p>
</div><h2>Checkpoint Therapeutics Stock Up 0.2 %</h2>
<div class="lb-trans"><h2>Checkpoint Therapeutics 股票上漲 0.2%</h2>
</div><p>CKPT traded up $0.01 during trading hours on Friday, hitting $4.04. 522,554 shares of the company's stock were exchanged, compared to its average volume of 1,124,079. The stock has a market cap of $197.29 million, a price-to-earnings ratio of -2.20 and a beta of 1.41. Checkpoint Therapeutics has a 1-year low of $1.38 and a 1-year high of $4.50. The stock's 50-day moving average is $3.32 and its two-hundred day moving average is $3.25.</p>
<div class="lb-trans"><p>CKPT 在週五的交易時段上漲了$0.01，達到$4.04。該公司股票交易量為 522,554 股，而其平均交易量為 1,124,079 股。該股票的市值為 1.9729 億美元，市盈率為-2.20，貝塔值為 1.41。Checkpoint Therapeutics 的 1 年最低價為$1.38，1 年最高價為$4.50。該股票的 50 日移動平均價為$3.32，200 日移動平均價為$3.25。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>CKPT has been the topic of a number of research analyst reports. HC Wainwright restated a &#34;neutral&#34; rating and set a $4.10 price objective on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th. Lake Street Capital reissued a &#34;hold&#34; rating and issued a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. Finally, D. Boral Capital restated a &#34;buy&#34; rating and issued a $4.80 price target (down from $9.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th.</p>
<div class="lb-trans"><p>CKPT 成為多份研究分析師報告的主題。HC Wainwright 在 3 月 11 日的報告中重申了 “中性” 評級，並將 Checkpoint Therapeutics 的目標價設定為$4.10。Lake Street Capital 在 3 月 10 日的研究報告中重新發布了 “持有” 評級，並將目標價下調至$4.10（之前為$7.00）。最後，D. Boral Capital 在 3 月 10 日的報告中重申了 “買入” 評級，並將目標價下調至$4.80（之前為$9.00）。</p>
</div><p><strong>Read Our Latest Stock Report on CKPT</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 CKPT 的最新股票報告</strong></p>
</div><h2>Insider Buying and Selling at Checkpoint Therapeutics</h2>
<div class="lb-trans"><h2>Checkpoint Therapeutics 的內部買賣</h2>
</div><p>In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 74,110 shares of the business's stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total transaction of $271,983.70. Following the transaction, the chief financial officer now owns 1,458,644 shares of the company's stock, valued at $5,353,223.48. The trade was a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, CEO James F. Oliviero III sold 9,233 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $3.41, for a total value of $31,484.53. Following the completion of the sale, the chief executive officer now directly owns 3,785,350 shares of the company's stock, valued at approximately $12,908,043.50. The trade was a 0.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 93,674 shares of company stock worth $336,011. Insiders own 2.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Checkpoint Therapeutics 的新聞中，首席財務官 William Garrett Gray 在 2 月 6 日的交易中出售了 74,110 股公司的股票。該股票以平均價格$3.67 出售，總交易額為$271,983.70。交易後，首席財務官現在持有 1,458,644 股公司的股票，價值$5,353,223.48。此次交易使其持股減少了 4.84%。該出售在向證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。此外，首席執行官 James F. Oliviero III 在 2 月 7 日的交易中出售了 9,233 股公司的股票。該股票以平均價格$3.41 出售，總價值為$31,484.53。出售完成後，首席執行官現在直接持有 3,785,350 股公司的股票，價值約為$12,908,043.50。此次交易使其持股減少了 0.24%。該出售的披露信息可在此找到。在過去三個月中，內部人士已出售 93,674 股公司股票，價值$336,011。內部人士持有公司股票的比例為 2.10%。</p>
</div><h2>About Checkpoint Therapeutics</h2>
<div class="lb-trans"><h2>關於 Checkpoint Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.</p>
<div class="lb-trans"><p>Checkpoint Therapeutics, Inc.是一家臨牀階段的免疫療法和靶向腫瘤學公司，專注於在美國和國際上獲取、開發和商業化新型治療方案，以治療實體腫瘤癌症患者。該公司的主要抗體產品候選藥物是 Cosibelimab，目前正在進行針對選定復發或轉移性癌症患者的 1 期臨牀試驗；CK-302 是一個針對血液惡性腫瘤和實體腫瘤的預臨牀試驗產品候選藥物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Checkpoint Therapeutics</li>
<li>Investing in Commodities: What Are They? How to Invest in Them</li>
<li>MarketBeat Week in Review – 03/24 - 03/28</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Checkpoint Therapeutics</li>
<li>投資商品：它們是什麼？如何投資？</li>
<li>MarketBeat 周度回顧 – 03/24 - 03/28</li>
<li>深入瞭解買賣差價</li>
<li>現在應該購買 UPS 股票嗎？深入分析其 5 年低點</li>
<li>ETF 會支付股息嗎？你需要知道的</li>
<li>4 只醫療保健股票大幅上漲——還有更多收益在後</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0tQVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CKPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Checkpoint Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Checkpoint Therapeutics 嗎？</h2>
</div><p>Before you consider Checkpoint Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Checkpoint Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Checkpoint Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Checkpoint Therapeutics 並不在名單上。</p>
</div><p>While Checkpoint Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Checkpoint Therapeutics 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Checkpoint Therapeutics（納斯達克股票代碼：CKPT）公佈季度財報結果